CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 310 enrolled
Drug / intervention
ABBV-CLS-7262 Dose 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05740813
NCT05740813Phase 3Completed
CompareCT.gov

HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

Merit E. Cudkowicz, MD·interventional·Posted Feb 23, 2023·Updated Nov 14, 2025

In Brief

A Phase 3 clinical trial evaluating ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2, and 1 other intervention for Amyotrophic Lateral Sclerosis. Completed, enrolled 310 participants across 1 site.

Detailed Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen F will evaluate the safety and efficacy of a single study drug, ABBV-CLS-7262, in participants with ALS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsCalico Life Sciences LLC

Timeline

Phase 3CompletedFinished
202420252026
First PostedFeb 23, 2023
Enrollment StartMar 23, 2023
Primary CompletionOct 3, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.4 years ago

Interventions

ABBV-CLS-7262 Dose 1drug

ABBV-CLS-7262 is administered orally once per day for 24 weeks.

ABBV-CLS-7262 Dose 2drug

ABBV-CLS-7262 is administered orally once per day for 24 weeks.

Matching Placebodrug

Matching placebo is administered orally once per day for 24 weeks.